Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
105 participants
OBSERVATIONAL
2011-03-31
2011-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Role of COX-2 Inhibition in Salt Sensitivity of Blood Pressure
NCT00624559
Naproxen Pharmacogenetic Study (Project 1, Aim 2)
NCT04449471
A Pharmacokinetics and Safety Study of Naproxcinod in Subjects With Impaired Renal Function
NCT00674856
An Open-Label Study to Evaluate the Effect of Age Upon the Pharmacokinetics of Androxal
NCT02169804
Study to Evaluate the Effect of Food Upon the Pharmacokinetics of Androxal
NCT02146391
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
There is a normal circadian rhythm to serum phosphorus with a mid-afternoon peak at approximately 3 PM and a nadir at approximately 7-11 AM. Furthermore it has been demonstrated that a fasting serum phosphorus level at 8 AM is NOT indicative of 24 hour mean serum phosphorus. Thus the relationship between salivary phosphorous and serum phosphorus may vary over the course of the day.
This is a single-center study in which saliva, urine, and serum will be collected at two time points in a minimum of 105 subjects with various degrees of renal function (not on dialysis). Assignment to the renal group will be based upon the Visit 2 estimated glomerular filtration rate value. Enrollment in each group will continue at random until the target of 15 subjects per group is achieved. It is possible that an individual group may exceed the target enrollment number as their assignment will occur retrospectively.
All subjects will be required to have their morning assessment conducted between the hours of 7AM and 11AM. Clinical chemistry, serum phosphorus, intact parathyroid hormone(iPTH), plasma fibroblast growth factor 23 (FGF-23),serum 1,25 di-hydroxyvitamin D, serum 25-OH vitamin D, and a spot urine will be collected. A 24-hour urine sample will also be collected.
Passive and stimulated salivary collection will occur. The salivary collection must occur in a fasting state with nothing to eat or drink for at least 90 minutes prior to the collection.
Subjects will be permitted to leave the facility. They will be instructed to consume a lunch of their choice between the hours of 1100AM and 1200PM. They will be instructed to eat nothing after 1200PM. Subjects will return to the clinic for Visit 3 as directed by the study staff. Visit 3 will be conducted between 1PM and 4PM. Laboratory assessments, salivary collections, and spot urines will be collected at Visit 3. A dietary recall of intake at Visit 2 and 3 will also be completed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Renal Function Group #1
Creatinine clearance \> 90 mL/min
No interventions assigned to this group
Renal Function Group #2
Creatinine clearance 60-69 mL/min
No interventions assigned to this group
Renal Function Group #3
Creatinine clearance 50-59 mL/min
No interventions assigned to this group
Renal Function Group #4
Creatinine clearance 40-49 mL/min
No interventions assigned to this group
Renal Function Group #5
Creatinine clearance 30-39 mL/min
No interventions assigned to this group
Renal Function Group #6
Creatinine clearance 20-29 mL/min
No interventions assigned to this group
Renal Function Group #7
Creatinine clearance \< 20 mL/min (not on dialysis)
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The subject has voluntarily signed and dated the most recent informed consent form approved by an Institutional Review Board (IRB).
Exclusion Criteria
* Receiving or has received an investigational product (or is currently using an investigational device) within 28 days prior to Visit 2.
* Evidence of active and clinically significant infection at Visit 2.
* Dental work within 48 hours prior to Visit 2.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CM&D Pharma Limited
INDUSTRY
Denver Nephrologists, P.C.
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Denver Nephrologists, P.C.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Geoffrey A Block, MD
Role: PRINCIPAL_INVESTIGATOR
Denver Nephrologists, PC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Denver Nephrologists, PC
Denver, Colorado, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Block GA, Persky MS, Shamblin BM, Baltazar MF, Singh B, Sharma A, Pergola P, Smits G, Comelli MC. Effect of salivary phosphate-binding chewing gum on serum phosphate in chronic kidney disease. Nephron Clin Pract. 2013;123(1-2):93-101. doi: 10.1159/000351850. Epub 2013 Jun 22.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CMD 003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.